About sugemalimab
PD-L1 immune checkpoint inhibitor
Used for
- With chemotherapy for certain adults with metastatic or unresectable non-small-cell lung cancer.
Usual adult dose
1200 mg by intravenous infusion every 3 weeks, with chemotherapy, according to the approved regimen.
Common side effects
- Fatigue
- Nausea and reduced appetite
- Rash or itching
- Immune-related inflammation, such as pneumonitis or hepatitis
Important warnings
- Can cause serious immune reactions affecting organs, sometimes after treatment ends.
- Report breathing changes, severe diarrhea, yellowing skin, or unusual weakness promptly.
- Infusion reactions can occur; treatment requires monitoring by healthcare professionals.
- Use only for the cancer types and combinations specified by local approval.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment and for at least 5 months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for at least 5 months after the last dose.
Interactions
- No major direct drug interactions are established; chemotherapy combinations have regimen-specific risks.
- Immune-suppressing medicines, including corticosteroids, may affect treatment or manage immune-related reactions.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.